Multiple Sclerosis; Stride Velocity 95th centile; Stride-level data; Wearable digital health technology
Abstract :
[en] [en] BACKGROUND: Wearable digital health technologies offer a unique opportunity to assess gait at the stride level in real-world settings. Walking impairment is a major cause of disability in multiple sclerosis (MS), yet current clinical metrics lack sensitivity to early and progressive changes in mobility.
METHODS: We conducted two studies (NCT04888689/NCT04882891) using a wearable device to develop and validate digital mobility outcome measures based on individual strides in patients with MS. First, we assessed technical performance in a controlled, single-center environment between September 12 and September 18, 2021. We then conducted a 12-month longitudinal study under daily living conditions across six sites between March 2021 and January 2024. The evaluated metrics included stride velocity 95th centile, walking distance 90th centile, and strides per hour.
FINDINGS: The controlled and longitudinal studies included 21 and 78 participants, respectively. The device demonstrated high stride detection accuracy (precision: 0·99) and a mean absolute error in stride velocity of 0·019 m/s. In the longitudinal study, stride velocity 95th percentile showed excellent reliability (ICC (2,1) = 0·97, SEM = 0·06) and strong agreement with Expanded Disability Status Scale (Spearman's rho = 0·65, p < 0·001) and Timed 25-Foot Walk (Spearman's rho = -0·71, p < 0·001), sensitivity to 12-month progression in both relapsing-remitting and progressive MS (p = 0·049 and p = 0·006, respectively), outperforming the Expanded Disability Status Scale. Walking distance 90th percentile and strides per hour were reliable and valid but less sensitive to progression.
INTERPRETATION: Stride velocity 95th percentile derived from real-world, stride-level data, provides a valid, reliable, and sensitive digital outcome for detecting MS progression. It may serve as an early indicator of progression and support the accelerated evaluation of treatments targeting progression.
FUNDING: This study was funded by F. Hoffmann-La Roche Ltd.
Disciplines :
Neurology
Author, co-author :
Poleur, Margaux ; Université de Liège - ULiège > Département des sciences cliniques
Willekens, Barbara ; Department of Neurology, Antwerp University Hospital, Antwerp, Belgium ; Faculty of Medicine and Health Sciences, Translational Neurosciences Research Group, University of Antwerp, Antwerp, Belgium
Degos, Bertrand; Neurology Department, Avicenne Hospital, APHP, Hôpitaux Universitaires de Paris-Seine Saint Denis (HUPSSD), Bobigny, France
Ricard, Damien; Service de Neurologie, Service de Santé des Armées, Hôpital d'Instruction des Armées de Percy, Clamart, France
van Pesch, Vincent; Cliniques Universitaires Saint-Luc, UCLouvain, Louvain, Belgium
Mélin, Annick; Departement of Neurology, CHC Mont-Legia, Liège, Belgium
Lommers, Emilie ; Université de Liège - ULiège > Département des sciences cliniques
De Keersmaecker, Anna-Victoria; Department of Neurology, Antwerp University Hospital, Antwerp, Belgium ; Faculty of Medicine and Health Sciences, Translational Neurosciences Research Group, University of Antwerp, Antwerp, Belgium
Coman, Irene; Neurology Department, Avicenne Hospital, APHP, Hôpitaux Universitaires de Paris-Seine Saint Denis (HUPSSD), Bobigny, France
Overell, James; F. Hoffmann-La Roche Ltd., Basel, Switzerland ; Department of Clinical Neuroscience, School of Medicine, Dentistry and Nursing, University of Glasgow, UK
Goodyear, Alexandra; Genentech, South San Francisco, CA, USA
Delmar, Paul; F. Hoffmann-La Roche Ltd., Basel, Switzerland
Wang, Qing; F. Hoffmann-La Roche Ltd., Basel, Switzerland
Hayward-Koennecke, Helen; F. Hoffmann-La Roche Ltd., Basel, Switzerland
Cluzeau, Céline; Sysnav, Vernon, France
Eggenspieler, Damien; Sysnav, Vernon, France
Strijbos, Paul; F. Hoffmann-La Roche Ltd., Basel, Switzerland
Servais, Laurent ; Université de Liège - ULiège ; MDUK Oxford Neuromuscular Centre, & NIHR, University of Oxford, UK
Masanneck L, Gieseler P, Gordon WJ, Meuth SG, Stern AD. Evidence from ClinicalTrials.gov on the growth of Digital Health Technologies in neurology trials. NPJ Digit Med. 2023;6(1). Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2021407100&from=export
Taylor KI, Staunton H, Lipsmeier F, Nobbs D, Lindemann M. Outcome measures based on digital health technology sensor data: data- and patient-centric approaches. NPJ Digit Med. 2020;3(1). Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2005662785&from=export
Servais L, Eggenspieler D, Poleur M, Grelet M, Muntoni F, Strijbos P, et al. First regulatory qualification of a digital primary endpoint to measure treatment efficacy in DMD. Nat Med. 2023;29(10):2391-2392. Available from: https://doi.org/10.1038/s41591-023-02459-5
Mico-Amigo ME, Bonci T, Paraschiv-Ionescu A, Ullrich M, Kirk C, Soltani A, et al. Assessing real-world gait with digital technology? Validation, insights and recommendations from the Mobilise-D consortium. J Neuroeng Rehabil. 2023;20(1):78. Available from: https://doi.org/10.1186/s12984-023-01198-5
van Unnik JWJ, Meyjes M, Janse van Mantgem MR, van den Berg LH, van Eijk RPA. Remote monitoring of amyotrophic lateral sclerosis using wearable sensors detects differences in disease progression and survival: a prospective cohort study. EBioMedicine. 2024;103:105104. Available from: https://doi.org/10.1016/j.ebiom.2024.105104
Michaud M, Guerin A, Dejean de La Batie M, Bancel L, Oudre L, Tricot A. The Analytical Validity of Stride Detection and Gait Parameters Reconstruction Using the Ankle-Mounted Inertial Measurement Unit Syde®. Sensors (Basel). 2024;24(8). Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L644110634&from=export
European Medicines Agency. EMA qualification opinion for SV95C as primary endpoint in studies in ambulatory Duchenne Muscular Dystrophy studies.. [cited 2025 Sep 15]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/qualification-opinion-stride-velocity-95th-centile-primary-endpoint-studies-ambulatory-duchenne-muscular-dystrophy-studies_en.pdf
Polhemus A, Ortiz LD, Brittain G, Chynkiamis N, Salis F, Gassner H, et al. Walking on common ground: a cross-disciplinary scoping review on the clinical utility of digital mobility outcomes. NPJ Digit Med. 2021;4(1). Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2013950595&from=export
Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Multiple Sclerosis Journal. 2020;26(14):1816-1821. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2007250194&from=export
Attfield KE, Jensen LT, Kaufmann M, Friese MA, Fugger L. The immunology of multiple sclerosis. Nat Rev Immunol. 2022;22(12):734-750. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2016510512&from=export
Lublin FD. New multiple sclerosis phenotypic classification. Eur Neurol. 2014;72:1-5. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L604018319&from=export
Sriwastava S, Elkhooly M, Amatya S, Shrestha K, Kagzi Y, Bhatia D, et al. Recent advances in the treatment of primary and secondary progressive Multiple Sclerosis. J Neuroimmunol. 2024;390. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2031409438&from=export
Fox RJ, Bar-Or A, Traboulsee A, Oreja-Guevara C, Giovannoni G, Vermersch P, et al. Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis. New England Journal of Medicine. 2025;392(19):1883-1892. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2039077868&from=export
Ontaneda D, Fox RJ, Chataway J. Clinical trials in progressive multiple sclerosis: Lessons learned and future perspectives. Lancet Neurol. 2015;14(2):208-223. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L602195187&from=export
European Medicines Agency. Draft qualification opinion of Multiple sclerosis clinical 4 outcome assessment. [cited 2025 Sep 15]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-qualification-opinion-multiple-sclerosis-clinical-outcome-assessment-mscoa_en.pdf
Heesen C, Haase R, Melzig S, Poettgen J, Berghoff M, Paul F, et al. Perceptions on the value of bodily functions in multiple sclerosis. Acta Neurol Scand. 2018;137(3):356-362. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L619612388&from=export
Dalla Costa G, Nos C, Zabalza A, Buron M, Magyari M, Sellebjerg F, et al. A wearable device perspective on the standard definitions of disability progression in multiple sclerosis. Multiple Sclerosis Journal. 2024;30(1):103-112. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2027947053&from=export
Goldman MD, Chen S, Kunisetty B, Gelfand JM, Cree BAC, Block VJ. Validating wearable step counts in multiple sclerosis research: a replication study. Front Neurol. 2025;16. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2041176441&from=export
Woelfle T, Bourguignon L, Lorscheider J, Kappos L, Naegelin Y, Jutzeler CR. Wearable Sensor Technologies to Assess Motor Functions in People With Multiple Sclerosis: Systematic Scoping Review and Perspective. J Med Internet Res. 2023;25. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2026637499&from=export
Food and Drug Administration. Letter of intent regarding the use of Actibelt in multiple sclerosis.
Karatsidis A, Angelini L, Scaramozza M, Bartholome E, Clinch SP, Shen C, et al. Characterizing gait in people with multiple sclerosis using digital data from smartphone sensors: A proposed framework. Multiple Sclerosis Journal. 2025;31(5):512-528. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2033358815&from=export
Inojosa H, Schriefer D, Ziemssen T. Clinical outcome measures in multiple sclerosis: A review. Autoimmun Rev. 2020;19(5). Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2005258700&from=export
Cederberg KLJ, Sikes EM, Bartolucci AA, Motl RW. Walking endurance in multiple sclerosis: Meta-analysis of six-minute walk test performance. Gait Posture. 2019;73:147-153. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2002326145&from=export
Goldsack JC, Coravos A, Bakker JP, Bent B, Dowling A V, Fitzer-Attas C, et al. Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for Biometric Monitoring Technologies (BioMeTs). NPJ Digit Med. 2020;3(1). Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2004718071&from=export
Parker RA, Scott C, Inácio V, Stevens NT. Using multiple agreement methods for continuous repeated measures data: a tutorial for practitioners. BMC Med Res Methodol. 2020;20(1):154.
Kirk C, Kuderle A, Mico-Amigo ME, Bonci T, Paraschiv-Ionescu A, Ullrich M, et al. Mobilise-D insights to estimate real-world walking speed in multiple conditions with a wearable device. Sci Rep. 2024;14(1):1754. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L643289295&from=export
Banks SA, Mazurek KA, Barnard L, Tobin WO, Ali F, Howe CL. Concordance of Wearable Sensors and Depth Cameras for Quantitative Gait Assessment in Multiple Sclerosis. Mult Scler Relat Disord. 2025;104. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2041330172&from=export
Montalban X, Graves J, Midaglia L, Mulero P, Julian L, Baker M, et al. A smartphone sensor-based digital outcome assessment of multiple sclerosis. Multiple Sclerosis Journal. 2022;28(4):654-664. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2013153980&from=export
Gidaro T, Gasnier E, Annoussamy M, Vissing J, Attarian S, Mozaffar T, et al. Home-based gait analysis as an exploratory endpoint during a multicenter phase 1 trial in limb girdle muscular dystrophy type R2 and facioscapulohumeral muscular dystrophy. Muscle Nerve. 2022;65(2):237-242. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2014305924&from=export
Alexander S, Peryer G, Gray E, Barkhof F, Chataway J. Wearable technologies to measure clinical outcomes in multiple sclerosis: A scoping review. Multiple Sclerosis Journal. 2021;27(11):1643-1656. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2005770090&from=export
Poleur M, Ulinici A, Daron A, Schneider O, Farra FD, Demonceau M, et al. Normative data on spontaneous stride velocity, stride length, and walking activity in a non-controlled environment. Orphanet J Rare Dis. 2021;16(1). Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2013196063&from=export
